Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study-Reference-Cited by-同舟云学术

Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study

Published:2022-09-02 Issue:4 Volume:3 Page:1316-1320
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Bulley Simon J.¹²,Santarsieri Anna¹^ORCID,Lentell Isabel C.¹,O'Sullivan Brendan³,Hodson Andrew⁴,Firth Oliver⁴,Sadullah Shalal⁵,Follows Annabel M.¹²,Karanth Mamatha⁶,Min Sandra Young⁶,Fowler Alexis⁷,Russell James¹,Uttenthal Benjamin J.¹,Hodson Daniel J.⁸⁹,Follows George A.¹

Affiliation:

1. Department of Haematology and Pharmacy Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus Cambridge UK

2. Murray Edwards College, University of Cambridge Huntingdon Road Cambridge UK

3. Pharmacy Department Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus Cambridge UK

4. Department of Haematology Ipswich Hospital Ipswich Suffolk UK

5. Department of Haematology James Paget University Hospitals NHS Foundation Trust Great Yarmouth Norfolk UK

6. Department of Haematology West Suffolk NHS Foundation Trust Bury St Edmunds Suffolk UK

7. Department of Haematology Hinchingbrooke Hospital North West Anglia NHS Foundation Trust Hinchingbrooke Huntingdon UK

8. Wellcome‐MRC Cambridge Stem Cell Institute University of Cambridge Puddicombe Way Cambridge UK

9. Department of Haematology University of Cambridge Cambridge UK

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.537

Reference14 articles.

1. Polatuzumab vedotin in relapsed or refractory diffuse large B‐cell lymphoma;Sehn LH;J Clin Oncol,2020

2. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

3. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial

4. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

5. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2024-07-13